New Delhi, Dec. 11 -- India's Contract Research, Development and Manufacturing Organisation (CRDMO) sector is poised for accelerated growth, supported by surging global pharma outsourcing, rising demand for complex modalities, and geopolitical supply-chain realignment, according to a report by Kotak Mutual Fund.

The report sourced from multiple industry studies notes that the Indian CRDMO market is projected to clock a 13 per cent CAGR between FY24 and FY29, expanding from USD 8.2 billion in 2024 to USD 15.4 billion by 2029.

CRDMO stands for Contract Research, Development, and Manufacturing Organization, a type of company in the pharmaceutical and biotech industry that offers integrated, end-to-end services.

India's global market share...